Key result
Rivaroxaban was not inferior to warfarin regarding the incidence and average number of micro embolic signals in patients with non-valvular atrial fibrillation.
Why the study?
In contrast to warfarin, the effect of non-vitamin K antagonist oral anticoagulants on microembolic signals in nonvalvular AF has not been fully researched.
Does rivaroxaban reduce the incidence and number of micro embolic signals compared to warfarin in patients with non-valvular atrial fibrillation?
Cohort (n=80)
Yes
Does rivaroxaban reduce the incidence and number of micro embolic signals compared to warfarin in patients with non-valvular atrial fibrillation?
Rivaroxaban 15 mg/day is comparable to optimized warfarin in preventing micro embolic signals in patients with non-valvular atrial fibrillation.
Answers are grounded in this paper and cite their sources.
May support rivaroxaban as warfarin alternative for microembolic signals in non-valvular AF; hypothesis-generating and requires randomized confirmation.
Background: Warfarin with optimized international normalization ratio (INR); is significantly affect the Micro embolic signals (MES), in many studies. Non vitamin k antagonist oral anticoagulants (NOACs) are recently approved for stroke prevention in non valvular AF. In contrast to Warfarin; effect of NOACs on MES is not yet fully researched. Aim: To determine the effect of NOACs on MES, in comparison to warfarin in non valvular AF, to reflect the potential embolization risk. Methods: The incidence and number of MES was studied in patients with non valvular AF. Two groups in the current study; the first, patients were put on warfarin with INR levels were optimized to (2-3), and considered as a control group. The second; patients were put on NOAC (rivaroxaban, 15 mg /day). Study patients were recruited from cardiology outpatient clinics and departments (Al-Azhar University hospitals; Cairo and New Damietta, Egypt). Patients of the both groups were subjected to MES detection and counting by transcranial Doppler ultrasonography (TCD) monitoring. Results: MES did not detected in 22.5% in study groups; no statistically significant differences between study groups. The incidence and number of MES; within the warfarin group; MES were detected in (30 patients, 75%), while within the rivaroxaban group (32 patients, 80%). The average number of MES; in group one were (11.65 ±7.20), and in group two (11.50 ±7.20), with no significant statistical difference also. Conclusion: The effect of warfarin and NOAC use is not statistically different and Rivaroxaban is not inferior to warfarin.
No takes yet. Share an insight, caveat, or question.
Zaki et al. (2023) conducted a cohort in Non-valvular atrial fibrillation (n=80). Rivaroxaban vs. Warfarin (optimized INR 2-3) was evaluated on Incidence of Micro embolic signals (MES). Rivaroxaban was not inferior to warfarin regarding the incidence and average number of micro embolic signals in patients with non-valvular atrial fibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: